Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma

Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Damato, BE, Dukes, J, Goodall, H, Carvajal, RD
Fformat:	Journal article
Cyhoeddwyd:	MDPI 2019

Eitemau Tebyg

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
gan: Sarah Howlett, et al.
Cyhoeddwyd: (2023-03-01)

Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
gan: Montazeri K, et al.
Cyhoeddwyd: (2023-02-01)

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
gan: Jessica C Hassel, et al.
Cyhoeddwyd: (2024-06-01)

Tebentafusp effect on the tumoural landscape in metastatic uveal melanoma – a post-mortem study
gan: C. Beland, et al.
Cyhoeddwyd: (2024-01-01)

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
gan: C. Gerard, et al.
Cyhoeddwyd: (2023-09-01)

538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
gan: Joseph Sacco, et al.
Cyhoeddwyd: (2021-11-01)

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
gan: Manuel Rodrigues, et al.
Cyhoeddwyd: (2024-10-01)

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
gan: Lucille Vitek, et al.
Cyhoeddwyd: (2024-12-01)

Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis
gan: Yating Dian, et al.
Cyhoeddwyd: (2024-12-01)

Tumor microenvironment (TME) features and serum cytokines in patients with metastatic uveal and cutaneous melanoma treated with tebentafusp
gan: O. Hamid, et al.
Cyhoeddwyd: (2024-01-01)

Comment on: “Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis”
gan: Muhammed Shabil, et al.
Cyhoeddwyd: (2024-12-01)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
gan: Selina Reiter, et al.
Cyhoeddwyd: (2023-05-01)

Response to comment on: “Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis”
gan: Danyao Chen, et al.
Cyhoeddwyd: (2024-12-01)

30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial
gan: Brendan Curti, et al.
Cyhoeddwyd: (2023-11-01)

Tebentafusp in first-line melanoma trials: An outperforming outlier
gan: Timothée Olivier, et al.
Cyhoeddwyd: (2022-06-01)

Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
gan: Alexander N Shoushtari, et al.
Cyhoeddwyd: (2024-11-01)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
gan: Jessica C Hassel, et al.
Cyhoeddwyd: (2023-06-01)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
gan: Shaheer Khan, et al.
Cyhoeddwyd: (2022-09-01)

Multiregional genetic evolution of metastatic uveal melanoma
gan: Daniel A. Rodriguez, et al.
Cyhoeddwyd: (2021-08-01)

Uveal melanoma: epidemiology, etiology, and treatment of primary disease
gan: Krantz BA, et al.
Cyhoeddwyd: (2017-01-01)

Darovasertib, a novel treatment for metastatic uveal melanoma
gan: Lei Cao, et al.
Cyhoeddwyd: (2023-07-01)

Prognostication of metastatic death in uveal melanoma patients: a Markov multi-state model.
gan: Eleuteri, A, et al.
Cyhoeddwyd: (2018)

Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma
gan: Ashley N. Anderson, et al.
Cyhoeddwyd: (2024-07-01)

GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome
gan: Nagla Abdel Karim, et al.
Cyhoeddwyd: (2018-01-01)

Treatment of uveal melanoma: where are we now?
gan: Jessica Yang, et al.
Cyhoeddwyd: (2018-02-01)

Tissue-Based Microarray Expression of Genes Predictive of Metastasis in Uveal Melanoma and Differentially Expressed in Metastatic Uveal Melanoma
gan: Hakan Demirci, et al.
Cyhoeddwyd: (2013-01-01)

Transarterial chemoembolization for patients with metastatic uveal melanoma in the liver
gan: B. I. Dolgushin, et al.
Cyhoeddwyd: (2016-09-01)

The role of PET/CT in the diagnosis of metastatic uveal melanoma
gan: S. V. Saakyan, et al.
Cyhoeddwyd: (2018-10-01)

Molecular profiling of driver events in metastatic uveal melanoma
gan: Joakim Karlsson, et al.
Cyhoeddwyd: (2020-04-01)

The immune cell landscape of metastatic uveal melanoma correlates with overall survival
gan: Anna Tosi, et al.
Cyhoeddwyd: (2021-05-01)

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication
gan: Ellie Swords, et al.
Cyhoeddwyd: (2024-10-01)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
gan: Vidhya Karivedu, et al.
Cyhoeddwyd: (2019-01-01)

Gamma knife radiosurgery for the treatment of uveal melanoma and uveal metastases
gan: Margaret M. Reynolds, et al.
Cyhoeddwyd: (2017-05-01)

Uveal Melanoma
gan: Vasilios P. Papastefanou, et al.
Cyhoeddwyd: (2011-01-01)

Specific human endogenous retroviruses predict metastatic potential in uveal melanoma
gan: Matthew L. Bendall, et al.
Cyhoeddwyd: (2022-05-01)

Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
gan: Alexander Z. Wei, et al.
Cyhoeddwyd: (2022-09-01)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
gan: Vidhya Karivedu, et al.
Cyhoeddwyd: (2019-01-01)

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.
gan: John W Crabb, et al.
Cyhoeddwyd: (2015-01-01)

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.
gan: Rosaria Gangemi, et al.
Cyhoeddwyd: (2012-01-01)

External validation of the Liverpool uveal melanoma prognosticator online
gan: DeParis, SW, et al.
Cyhoeddwyd: (2016)